Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
about
Understanding the Functional Plasticity in Neural Networks of the Basal Ganglia in Cocaine Use Disorder: A Role for Allosteric Receptor-Receptor Interactions in A2A-D2 Heteroreceptor ComplexesAn Anti-Parkinson's Disease Drug via Targeting Adenosine A2A Receptor Enhances Amyloid-β Generation and γ-Secretase ActivityModulation of excitatory neurotransmission by neuronal/glial signalling molecules: interplay between purinergic and glutamatergic systems.Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging.Hyperkinetic disorders and loss of synaptic downscaling.How does adenosine control neuronal dysfunction and neurodegeneration?Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF.Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum.Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine ModulationPathological overproduction: the bad side of adenosine.An Automated Home-Cage System to Assess Learning and Performance of a Skilled Motor Task in a Mouse Model of Huntington's DiseasePurinergic Signalling: Therapeutic Developments.Adenosine A2A Receptors in the Amygdala Control Synaptic Plasticity and Contextual Fear Memory.In Vivo PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease.Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.Adenosine A2A Receptor Signaling in the Immunopathogenesis of Experimental Autoimmune Encephalomyelitis.Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington's Disease.Adenosine A2A Receptors Control Glutamatergic Synaptic Plasticity in Fast Spiking Interneurons of the Prefrontal Cortex.Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges.The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease
P2860
Q28071958-57CF35FE-F3DE-4139-8D5F-1CC6494723E9Q28553493-4724D77F-C41E-4482-A81F-6A726558F2BDQ38358456-7CA8F898-5186-435F-8CA2-4712AAC2FC00Q38765118-AA020497-D505-4499-9A35-294F7DDEF708Q38847727-53734016-E6F3-489C-BC57-69212AA5E3B0Q38882782-2C66C4C0-3C06-4533-AF78-2216AB37259CQ38928777-8527631A-5C36-4F53-9B20-63FA0D5357A7Q39013000-589D3325-19E4-4585-9352-1A469B4AE82DQ39041217-0087E97A-9D03-4D61-B93B-BE750E582859Q39157893-2EDB0315-2179-4EE0-ADAA-79FAA8D25575Q41720511-695B6052-B7D0-4ECF-AB7C-93253823D2D8Q42367885-1CD05974-D5B0-4FEE-9A1F-02E6BD15F678Q42701014-8BCDF1AD-F881-4680-91AD-0F5C1759CABAQ47853027-0EA46151-7E0B-4F17-8D82-6C259EDF099FQ50531505-6E04068B-805A-4616-B81E-1ECBA77829DDQ52348482-84906D00-410E-47A5-9C62-CD442C040AA0Q52590778-E3354F88-12F7-47B5-85AD-2062056CE8FDQ53418752-14DD4258-4517-42AB-8A41-19DE80BA43D9Q55266660-FC4F9F64-B1B6-4CC9-B5E8-4BC59B9611B0Q55297865-B4A0C088-1506-470E-B303-989E0986615DQ57896358-7027A253-549B-410B-9DB5-E4767FAA2C0E
P2860
Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Inactivation of adenosine A2A ...... f Huntington's disease models.
@en
Inactivation of adenosine A2A ...... f Huntington's disease models.
@nl
type
label
Inactivation of adenosine A2A ...... f Huntington's disease models.
@en
Inactivation of adenosine A2A ...... f Huntington's disease models.
@nl
prefLabel
Inactivation of adenosine A2A ...... f Huntington's disease models.
@en
Inactivation of adenosine A2A ...... f Huntington's disease models.
@nl
P2093
P50
P1476
Inactivation of adenosine A2A ...... f Huntington's disease models.
@en
P2093
Jiang-Fan Chen
Marie-Pierce Payen
Yu-Mei Wang
Yuanguo Zhou
P356
10.1016/J.NBD.2015.03.030
P577
2015-04-16T00:00:00Z